Patents by Inventor Thomas Carr Scanlon

Thomas Carr Scanlon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic charge engineered variants of lysozyme and methods for using same to treat infections
    Patent number: 9950041
    Abstract: The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrodial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: April 24, 2018
    Inventors: Karl Edwin Griswold, Thomas Carr Scanlon
  • Therapeutic Charge Engineered Variants of Lysozyme and Methods for Using Same to Treat Infections
    Publication number: 20170128546
    Abstract: The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrodial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug.
    Type: Application
    Filed: July 6, 2015
    Publication date: May 11, 2017
    Inventors: Karl Edwin Griswold, Thomas Carr Scanlon
  • Therapeutic charge engineered variants of lysozyme and methods for using same to treat infections
    Patent number: 9074201
    Abstract: The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrobial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: July 7, 2015
    Inventors: Karl Griswold, Thomas Carr Scanlon
  • Therapeutic Charge Engineered Variants of Lysozyme and Methods for Using Same to Treat Infections
    Publication number: 20130058912
    Abstract: The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrobial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug.
    Type: Application
    Filed: January 19, 2010
    Publication date: March 7, 2013
    Inventors: Karl Griswold, Thomas Carr Scanlon